Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 19 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

42%

8 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
6(31.6%)
Phase 3
5(26.3%)
Phase 4
3(15.8%)
Phase 2
2(10.5%)
Early Phase 1
2(10.5%)
N/A
1(5.3%)
19Total
Phase 1(6)
Phase 3(5)
Phase 4(3)
Phase 2(2)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials
NCT07545564Phase 4Enrolling By Invitation

A Study on Mucosal Specific IgA Immunokinetics After Administration of Nasal Spray Live Attenuated Influenza Vaccine

Role: lead

NCT07500207Phase 3Enrolling By Invitation

A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)

Role: lead

NCT07492303Phase 1Not Yet Recruiting

A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)

Role: lead

NCT07349017Phase 1Not Yet Recruiting

A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant)

Role: lead

NCT07338786Phase 1Enrolling By Invitation

A Phase I Clinical Trial to Evaluate the Safety of Different Immunization Schedules of a Lyophilized Human Rabies Vaccine (Human Diploid Cell)

Role: lead

NCT07330440Phase 1Enrolling By Invitation

A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination

Role: lead

NCT07133802Phase 3Not Yet Recruiting

Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination

Role: lead

NCT07112144Phase 3Recruiting

Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial

Role: lead

NCT06961721Phase 4Not Yet Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older

Role: lead

NCT06548139Phase 2Not Yet Recruiting

Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials

Role: lead

NCT06360250Early Phase 1Not Yet Recruiting

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation

Role: lead

NCT06280144Phase 4Unknown

Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine

Role: lead

NCT05832073Early Phase 1Unknown

Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1

Role: lead

NCT05284851Phase 2Unknown

The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine

Role: lead

NCT05189548Phase 1Unknown

To Evaluate the Safety and Primary Immunogenicity of Cell-free (Three-component) Combination Vaccine for Phase I Immunogenicity in Children and Infants

Role: lead

NCT04334577Phase 3Completed

Study on Efficacy of Attenuated Zoster Vaccine, Live

Role: lead

NCT05056519Phase 1Unknown

The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine

Role: lead

NCT04825340Not ApplicableUnknown

To Explore a Bridging Index for the Effectiveness of the Clinical Trial

Role: lead

NCT02964065Phase 3Completed

A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)

Role: lead

All 19 trials loaded